Biomarkers in acute kidney injury, sepsis and ARDS: Guiding clinicians…. but where to?

Open access


  • 1. Honore PM, Jacobs R, Joannes-Boyau O, Verfaillie L, De Regt J, Van Gorp V, et al. Biomarkers for early diagnosis of AKI in the ICU: Ready for prime time use at the bedside? Ann Intensive Care 2012;2:24.

  • 2. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: A multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011;57:1752-61.

  • 3. Haase M, Kellum JA, Ronco C. Subclinical AKI--an emerging syndrome with important consequences. Nat Rev Nephrol 2012;8:735-9.

  • 4. Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. Crit Care 2012;16:313.

  • 5. Ronco C, Stacul F, McCullough PA. Subclinical acute kidney injury (AKI) due to iodine-based contrast media. Eur Radiol 2013;23:319-23.

  • 6. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013;17:R25.

  • 7. Hoste EA, McCullough PA, Kashani K, Chawla LS, Joannidis M, Shaw AD, et al. Sapphire Investigators. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 2014;29:2054-61.

  • 8. Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta 2014;440:97-103.

  • 9. Yoo H, Ku SK, Kim SW, Bae JS. Early Diagnosis of Sepsis Using Serum Hemoglobin Subunit Beta. Inflammation 2014 Oct 23. [Epub ahead of print].

  • 10. Hjortrup PB, Haase N, Treschow F, Møller MH, Perner A. Predictive value of NGAL for use of renal replacement therapy in patients with severe sepsis. Acta Anaesthesiol Scand 2015;59:25-34.

  • 11. Ronco C, Legrand M, Goldstein SL, Hur M, Tran N, Howell EC, et al.Neutrophil gelatinase-associated lipocalin: Ready for routine clinical use? An international perspective. Blood Purif 2014;37:271-85.